|
Olaparib
|
2014.12 (FDA)
|
Late-line monotherapy
|
Adult patients with advanced recurrent HGSOCs with germline BRCA mutations, who have received three or more prior lines of chemotherapy
|
Study 42
|
|
Rucaparib
|
2016.12 (FDA)
|
Late-line monotherapy
|
Adult patients with advanced recurrent EOCs with germline BRCA mutations, who have received two or more prior lines of chemotherapy
|
Study 10 & ARIEL2
|
|
Niraparib
|
2017.3 (FDA)
|
Maintenance therapy
|
Adult patients with recurrent EOCs, who had either a complete or a partial response to platinum-based chemotherapy
|
NOVA
|
|
Olaparib
|
2017.8 (FDA)
|
Maintenance therapy
|
Adult patients with recurrent EOCs, who had either a complete or a partial response to platinum-based chemotherapy
|
Study 19 & SOLO-2
|
|
Rucaparib
|
2018.4 (FDA)
|
Maintenance therapy
|
ARIEL3
|
|
Olaparib
|
2018.8 (NMPA)
|
Maintenance therapy
|
Study 19 & SOLO-2
|
|
Olaparib
|
2018.12 (FDA)
|
Maintenance therapy
|
Newly diagnosed adult EOC patients with BRCA mutations, who had either a complete or a partial response to first-line platinum-based chemotherapy (frontline maintenance therapy)
|
SOLO-1
|
|
Niraparib
|
2019.10 (FDA)
|
Late-line monotherapy
|
Recurrent adult EOC after three or more prior lines of chemotherapy: who are BRCA mutated or HRD-positive and platinum sensitive
|
QUADRA
|
|
Olaparib
|
2019.12 (NMPA)
|
Maintenance therapy
|
Newly diagnosed adult EOC patients with BRCA mutations, who had either a complete or a partial response to first-line platinum-based chemotherapy (frontline maintenance therapy)
|
SOLO-1
|
|
Niraparib
|
2019.12 (NMPA)
|
Maintenance therapy
|
Adult patients with recurrent EOCs, who had either a complete or a partial response to platinum-based chemotherapy
|
NOVA
|
